AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1460196 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut protein extracts treated with enzymes in the immobilized digestive enzyme assay system
Number of subjects: 12
Study 1460196 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean protein extracts treated with enzymes in the immobilized digestive enzyme assay system
Number of subjects: 12
Study 1460196 — intervention group
Group type: COMPARATOR
Intervention: Peanut protein extracts subjected to thermal denaturation
Number of subjects: 12
Study 1460196 — intervention group
Group type: COMPARATOR
Intervention: Soybean protein extracts subjected to thermal denaturation
Number of subjects: 12
Study 1460196 — intervention group
Group type: COMPARATOR
Intervention: Chemical denaturation of peanut and soybean protein extracts
Number of subjects: 12
Study 6368610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 250 mg q.i.d.
Number of subjects: 10
Study 6368610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31471248 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + MCT
Number of subjects: 50
Study 31471248 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 50
Study 30663788 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + EMD
Number of subjects: 38
Study 30663788 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 38
Study 28373523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire simulation training
Number of subjects: 19
Study 26110891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 6% v/v EtOH (alcohol)
Number of subjects: 35
Study 26110891 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 35
Study 23464643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention consisting of eight sessions
Number of subjects: 60
Study 21480681 — intervention group
Group type: EXPERIMENTAL
Intervention: Static and dynamic risk factors (alcohol dependence severity, treatment history, marital status, psychiatric symptoms, negative affect, craving, stress)
Number of subjects: 1383
Study 21480681 — intervention group
Group type: EXPERIMENTAL
Intervention: Static risk factors (alcohol dependence severity, treatment history, marital status, psychiatric symptoms)
Number of subjects: 1383
Study 21480681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic risk factors (changes in negative affect, craving, stress)
Number of subjects: 1383
Study 19588684 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural administration of bupivacaine with midazolam (group B)
Number of subjects: 49
Study 19588684 — intervention group
Group type: COMPARATOR
Intervention: Continuous thoracic epidural administration of bupivacaine (group A)
Number of subjects: 49
Study 16816756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-led intervention
Number of subjects: 0
Study 16816756 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologist-led intervention
Number of subjects: 0
Study 16816756 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12798539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg every 6 hours (group 1)
Number of subjects: 84
Study 12798539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg every 3 hours (group 2)
Number of subjects: 84
Study 12798539 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of vaginal misoprostol 600 microg followed by oral misoprostol 200 microg every 3 hours (group 3)
Number of subjects: 84
Study 10847283 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicoprofen (ibuprofen 200 mg/hydrocodone 7.5 mg)
Number of subjects: 125
Study 10847283 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (acetaminophen 300 mg/codeine 30 mg)
Number of subjects: 125
Study 10847283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 8633398 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 224
Study 8633398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 1728377 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of mitomycin C (5 mg/m2, intravenously) every 6 weeks
Number of subjects: 67
Study 1728377 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of mitomycin C (20 mg/m2, intravenously) every 6 weeks
Number of subjects: 67
Study 6233879 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 950
Study 31207908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet for Weight Loss (LFWL)
Number of subjects: 21
Study 31207908 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet for Weight Maintenance (LFWM)
Number of subjects: 21
Study 31207908 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (used in both diets)
Number of subjects: 21
Study 31207908 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NO and CRP measurements (for both diets)
Number of subjects: 21
Study 30201043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangbi Waixi (TW) decoction foot bath
Number of subjects: 640
Study 27044304 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based relapse prevention program (e-SMARPP) consisting of six modules with tailored feedback from health care professionals and 8 weeks of self-monitoring.
Number of subjects: 0
Study 27044304 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring group (control group)
Number of subjects: 0
Study 27044304 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based relapse prevention program (e-SMARPP)
Number of subjects: 0
Study 24564877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) intervention
Number of subjects: 142
Study 24564877 — intervention group
Group type: COMPARATOR
Intervention: Usual education (control)
Number of subjects: 142
Study 23102183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Eating (MB-EAT-D)
Number of subjects: 52
Study 23102183 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Self-Management Education (Smart Choices)
Number of subjects: 52
Study 23102183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 20194878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg/90 mg twice daily)
Number of subjects: 98
Study 20194878 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg/75 mg once daily)
Number of subjects: 98
Study 20194878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor therapy
Number of subjects: 98
Study 20194878 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel therapy
Number of subjects: 98
Study 17095943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient infusion of Ensure at 1 kcal/min
Number of subjects: 31
Study 17095943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient infusion of Ensure at 2 kcal/min
Number of subjects: 31
Study 17095943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient infusion in patients with feed intolerance
Number of subjects: 31
Study 17095943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient infusion in patients with impaired renal function
Number of subjects: 31
Study 16193338 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 24
Study 16193338 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional + Resistance Training (FRT)
Number of subjects: 24
Study 16193338 — intervention group
Group type: COMPARATOR
Intervention: Functional Training (FT)
Number of subjects: 24
Study 12038497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 hours of timing training with an instrument designed to train participants to tap their hands and feet in synchrony with target sounds.
Number of subjects: 40
Study 12038497 — intervention group
Group type: COMPARATOR
Intervention: Control condition involved reading literature about how to improve golf swing.
Number of subjects: 40
Study 9926181 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketoprofen (1 mg kg-1 followed by an infusion of 1 mg kg-1 over 2 h)
Number of subjects: 59
Study 9926181 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketoprofen
Number of subjects: 59
Study 9926181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 59
Study 7676786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 Hz Single Twitch Stimulation (STS)
Number of subjects: 100
Study 7676786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 Hz Single Burst Stimulation (SBS)
Number of subjects: 100
Study 7676786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 Hz Single Twitch Stimulation (STS)
Number of subjects: 100
Study 7676786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 Hz Single Burst Stimulation (SBS)
Number of subjects: 100
Study 1693062 — intervention group
Group type: EXPERIMENTAL
Intervention: rG-CSF administered intravenously at a dose of 100 micrograms/m2
Number of subjects: 53
Study 1693062 — intervention group
Group type: EXPERIMENTAL
Intervention: rG-CSF administered subcutaneously at a dose of 75 micrograms
Number of subjects: 53
Study 1693062 — intervention group
Group type: EXPERIMENTAL
Intervention: rG-CSF administered subcutaneously at a dose of 100 micrograms/m2
Number of subjects: 53
Study 1693062 — intervention group
Group type: EXPERIMENTAL
Intervention: rG-CSF administered subcutaneously at a dose of 125 micrograms
Number of subjects: 53
Study 1693062 — intervention group
Group type: COMPARATOR
Intervention: Control group (without rG-CSF)
Number of subjects: 53
Study 7387806 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental administration of thiopentone (50‐mg increments every 15 s)
Number of subjects: 20
Study 7387806 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of thiopentone (4‐mg kg‐1)
Number of subjects: 20
Study 31875276 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide 600-μg twice daily
Number of subjects: 162
Study 31875276 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide 900-μg twice daily
Number of subjects: 162
Study 31125538 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior technique with 2.7 mL of anesthetic
Number of subjects: 108
Study 31125538 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior technique with 1.8 mL of anesthetic
Number of subjects: 108
Study 31125538 — intervention group
Group type: COMPARATOR
Intervention: Conventional IANB with 1.8 mL of anesthetic
Number of subjects: 108
Study 31125538 — intervention group
Group type: COMPARATOR
Intervention: Conventional IANB with 2.7 mL of anesthetic
Number of subjects: 108
Study 31125538 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI analysis of anterior technique
Number of subjects: 108
Study 27173671 — intervention group
Group type: EXPERIMENTAL
Intervention: Front treatment (targeted product placed in the front)
Number of subjects: 886
Study 27173671 — intervention group
Group type: COMPARATOR
Intervention: Back treatment (targeted product placed in the back)
Number of subjects: 886
Study 27173671 — intervention group
Group type: EXPERIMENTAL
Intervention: Boxed intervention (targeted product presented in its original box)
Number of subjects: 886
Study 27173671 — intervention group
Group type: COMPARATOR
Intervention: Unboxed treatment (targeted product presented unboxed)
Number of subjects: 886
Study 25884634 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Triple P for Preterm infants
Number of subjects: 330
Study 25884634 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 330
Study 23981052 — intervention group
Group type: EXPERIMENTAL
Intervention: Early follicular phase (low hormone levels)
Number of subjects: 0
Study 23981052 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase (high hormone levels)
Number of subjects: 0
Study 22234084 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic stenting (EPS)
Number of subjects: 41
Study 22234084 — intervention group
Group type: COMPARATOR
Intervention: Control (no EPS)
Number of subjects: 41
Study 19618262 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG‐biofeedback
Number of subjects: 30
Study 19618262 — intervention group
Group type: COMPARATOR
Intervention: Control condition (information about bowel functioning and counseling)
Number of subjects: 30
Study 17901096 — intervention group
Group type: EXPERIMENTAL
Intervention: Various assessment tools for measuring emesis
Number of subjects: 0
Study 17901096 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific and global assessment tools
Number of subjects: 0
Study 17901096 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily clinical assessment, prevalence surveys, randomized controlled trial settings
Number of subjects: 0
Study 12447512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg daily
Number of subjects: 204
Study 12447512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 10512345 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 1% cream applied twice daily for 3 weeks
Number of subjects: 22
Study 10512345 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 200 mg once weekly for 3 weeks
Number of subjects: 22
Study 8835618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 30
Study 8835618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Number of subjects: 30
Study 8835618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 23 mg
Number of subjects: 30
Study 8835618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (both doses)
Number of subjects: 30
Study 2201165 — intervention group
Group type: EXPERIMENTAL
Intervention: GGG‐ORS
Number of subjects: 92
Study 2201165 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS
Number of subjects: 92
Study 6892984 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 198
Study 6892984 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy
Number of subjects: 198
Study 30038044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 1298
Study 30038044 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 1298
Study 30038044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAF and TDF
Number of subjects: 1298
Study 28963118 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell depletion
Number of subjects: 0
Study 26481741 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postsurgical temozolomide (TMZ) plus standard concomitant radiochemotherapy regimen
Number of subjects: 99
Study 26481741 — intervention group
Group type: COMPARATOR
Intervention: Standard concomitant radiochemotherapy regimen
Number of subjects: 99
Study 26481741 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postsurgical temozolomide (TMZ)
Number of subjects: 99
Study 23666915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 0.3 mg/kg
Number of subjects: 0
Study 23666915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 3 mg/kg
Number of subjects: 0
Study 23666915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 10 mg/kg
Number of subjects: 0
Study 23666915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 10 mg/kg (treatment-naïve patients)
Number of subjects: 0
Study 23666915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 10 mg/kg (retreatment upon disease progression)
Number of subjects: 0
Study 22030767 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective Adaptive Process (RAP), a 12-week intensive QI process
Number of subjects: 7
Study 22030767 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of residents in the QI process
Number of subjects: 7
Study 22030767 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger practices with resources and characteristics supporting QI
Number of subjects: 7
Study 22030767 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental approach to QI for smaller practices
Number of subjects: 7
Study 18469239 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCS
Number of subjects: 34
Study 18469239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 34
Study 18469239 — intervention group
Group type: COMPARATOR
Intervention: Fructose
Number of subjects: 34
Study 18469239 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 34
Study 17034372 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine cream
Number of subjects: 54
Study 17034372 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 54
Study 17034372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Eflornithine + laser)
Number of subjects: 54
Study 14617299 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 85
Study 9989685 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice (2.4 g/d)
Number of subjects: 83
Study 9989685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 7750388 — intervention group
Group type: EXPERIMENTAL
Intervention: On demand ultrasound
Number of subjects: 308
Study 7750388 — intervention group
Group type: COMPARATOR
Intervention: Routine ultrasound
Number of subjects: 308
Study 2249116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 53
Study 2249116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 119975 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol
Number of subjects: 420
Study 119975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephazolin
Number of subjects: 420
Study 119975 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol plus Cephazolin
Number of subjects: 420
Study 119975 — intervention group
Group type: COMPARATOR
Intervention: Local nitrofurantoin treatment
Number of subjects: 420
Study 119975 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment of the vagina
Number of subjects: 420
Study 30199448 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell velocity during the bench press (BP)
Number of subjects: 40
Study 30199448 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight velocity during the 2 leg press (2LP)
Number of subjects: 40
Study 30199448 — intervention group
Group type: COMPARATOR
Intervention: Machine-based exercise
Number of subjects: 40
Study 30777368 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC
Number of subjects: 180
Study 30777368 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision®
Number of subjects: 180
Study 30777368 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 180
Study 29208752 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-Glutamine (AlaGln) supplemented PD fluid
Number of subjects: 20
Study 29208752 — intervention group
Group type: COMPARATOR
Intervention: Standard PD fluid
Number of subjects: 20
Study 26999113 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline treatment
Number of subjects: 163
Study 26999113 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 163
Study 25675664 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration (5 ml, 50 mg/10 ml)
Number of subjects: 44
Study 25675664 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride infiltration
Number of subjects: 44
Study 25675664 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration
Number of subjects: 44
Study 22436595 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational and cognitive behavioural stabilizing group treatment (experimental treatment; EXP) added to treatment as usual (TAU)
Number of subjects: 29
Study 22436595 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 29
Study 20630920 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 45
Study 20630920 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% gelatine
Number of subjects: 45
Study 20630920 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 45
Study 20630920 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 and 4% gelatine
Number of subjects: 45
Study 17990133 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared-decision making
Number of subjects: 636
Study 17990133 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for shared-decision making
Number of subjects: 636
Study 15866397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 5% cream
Number of subjects: 55
Study 15866397 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 55
Study 11935040 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum immune complexes (IC) concentration in stroke patients
Number of subjects: 179
Study 11935040 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Chlamydia pneumoniae antigen in IC
Number of subjects: 179
Study 11935040 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti-CMV antibodies in IC
Number of subjects: 179
Study 11935040 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological status and 30-day mortality rate
Number of subjects: 179
Study 11935040 — intervention group
Group type: COMPARATOR
Intervention: Control groups (old and young)
Number of subjects: 179
Study 9479343 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoPap System
Number of subjects: 0
Study 9479343 — intervention group
Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 0
Study 7872228 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g n-3 FAs/d for 6 weeks followed by 3 g/d for 12 weeks
Number of subjects: 0
Study 29677641 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (oral tegafur-uracil) at 500-600 mg/day for 5 days followed by 2-day rest for 1 year
Number of subjects: 1982
Study 29677641 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1982
Study 29677641 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (oral tegafur-uracil)
Number of subjects: 1982
Study 28731602 — intervention group
Group type: EXPERIMENTAL
Intervention: Remer and Manz equation
Number of subjects: 13
Study 28731602 — intervention group
Group type: EXPERIMENTAL
Intervention: Frassetto et al. equation one
Number of subjects: 13